A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial):study protocol

Mullen, Michael J, Flather, Marcus D, Jin, Xu Yu, Newman, William G, Erdem, Guliz, Gaze, David, Valencia, Oswaldo, Banya, Winston, Foley, Claire E and Child, Anne (2013) A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial):study protocol. Trials, 14 (1). p. 408. ISSN 1745-6215

Full text not available from this repository. (Request a copy)

Abstract

Cardiovascular complications are the leading cause of mortality and morbidity in Marfan syndrome (MFS), a dominantly inherited disorder caused by mutations in the gene that encodes fibrillin-1. There are approximately 18,000 patients in the UK with MFS. Current treatment includes careful follow-up, beta blockers, and prophylactic surgical intervention; however, there is no known treatment which effectively prevents the rate of aortic dilatation in MFS. Preclinical, neonatal, and pediatric studies have indicated that angiotensin receptor blockers (ARBs) may reduce the rate of aortic dilatation. This trial will investigate the effects of irbesartan on aortic dilatation in Marfan syndrome.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 06 Jan 2014 14:58
Last Modified: 21 Apr 2020 22:33
URI: https://ueaeprints.uea.ac.uk/id/eprint/46229
DOI: 10.1186/1745-6215-14-408

Actions (login required)

View Item View Item